Forskning ved Københavns Universitet - Københavns Universitet


Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt


  • Sarah H Kim
  • Arnaud Da Cruz Paula
  • Thais Basili
  • Higinio Dopeso
  • Rui Bi
  • Fresia Pareja
  • Edaise M da Silva
  • Rodrigo Gularte-Mérida
  • Zhen Sun
  • Sho Fujisawa
  • Caitlin G Smith
  • Lorenzo Ferrando
  • Ana Paula Martins Sebastião
  • Yonina Bykov
  • Anqi Li
  • Catarina Silveira
  • Charles W Ashley
  • Anthe Stylianou
  • Pier Selenica
  • Wesley R Samore
  • Achim A Jungbluth
  • Dmitriy Zamarin
  • Nadeem R Abu-Rustum
  • Robert A Soslow
  • Jorge S Reis-Filho
  • Esther Oliva
  • Britta Weigelt

Sclerosing stromal tumor (SST) of the ovary is a rare type of sex cord-stromal tumor (SCST), whose genetic underpinning is currently unknown. Here, using whole-exome, targeted capture and RNA-sequencing, we report recurrent FHL2-GLI2 fusion genes in 65% (17/26) of SSTs and other GLI2 rearrangements in additional 15% (4/26) SSTs, none of which are detected in other types of SCSTs (n = 48) or common cancer types (n = 9,950). The FHL2-GLI2 fusions result in transcriptomic activation of the Sonic Hedgehog (SHH) pathway in SSTs. Expression of the FHL2-GLI2 fusion in vitro leads to the acquisition of phenotypic characteristics of SSTs, increased proliferation, migration and colony formation, and SHH pathway activation. Targeted inhibition of the SHH pathway results in reversal of these oncogenic properties, indicating its role in the pathogenesis of SSTs. Our results demonstrate that the FHL2-GLI2 fusion is likely the oncogenic driver of SSTs, defining a genotypic-phenotypic correlation in ovarian neoplasms.

TidsskriftNature Communications
Udgave nummer1
Sider (fra-til)44
StatusUdgivet - 2 jan. 2020

ID: 233658622